However, sotorasib, a small molecule binding to a specific KRAS G12C mutation, was developed and showed promising efficacy for KRAS G12C mutated NSCLC [7], leading to the approval by the Food and Drug Administration (FDA) in May 2021. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.